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http://dx.doi.org/10.1016/j.jacl.2016.0BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare, inherited condition
resulting in severely elevated low-density lipoprotein cholesterol levels (LDL-C) leading to premature
cardiovascular disease and, often, death. Mipomersen is an antisense oligonucleotide that inhibits
apolipoprotein B (apo B) synthesis, lowering LDL-C levels. Mipomersen has demonstrated efficacy
in adult HoFH patients, possibly providing a therapeutic option for pediatric patients. Study objectives
were to summarize mipomersen efficacy and safety in the pediatric cohort of a phase 3 randomized
controlled trial (RCT) and subsequent open-label extension study (OLE).
METHODS: Seven patients aged 12–18 years were randomized to 200-mg mipomersen or placebo
weekly (26 weeks) and received mipomersen in the OLE (52 or 104 weeks). Plasma LDL-C and
apo B concentrations and adverse events were assessed.
RESULTS: All pediatric patients completed the RCT and entered OLE. The 3 mipomersen patients
in the RCT experienced mean reductions from baseline to RCT end of 42.7% and 46.1% for LDL-C
and apo B, respectively. Of the 4 placebo patients, 3 responded well to mipomersen during OLE,
with reductions in LDL-C of 26.5%–42.1%. Three patients completed OLE treatment, and 4 patients
discontinued therapy due to adverse events. Lipid level fluctuations were observed and were likely due
to poor compliance.
CONCLUSIONS: Long-term mipomersen treatment was successful regarding efficacy parameters for
pediatric HoFH patients. The safety profile was consistent with other phase 3 clinical trials. Long-term
compliance was an issue. Measures supporting adherence should be encouraged.
 2016 Sanofi-Genzyme. Published by Elsevier Inc. On behalf of National Lipid Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).epartment of Medicine, Johannes-
ohannesburg 2193, South Africa.
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2.018Introduction
Homozygous familial hypercholesterolemia (HoFH) is a
rare condition usually caused by mutations in both copies
of the low-density lipoprotein (LDL) receptor gene,National Lipid Association. This is an open access article under the
Raal et al Pediatric experience with mipomersen 861resulting in very high plasma levels of LDL cholesterol
(LDL-C) from birth.1 Based on a recent Dutch study, the
prevalence of HoFH was estimated to be approximately 1
in 300,000 individuals.2 In untreated patients with HoFH,
atherosclerosis develops rapidly with clinically significant
atherosclerotic vascular disease and often with sudden
death from myocardial infarction or acute coronary insuffi-
ciency before the age of 30 years.1,3 Lowering LDL-C con-
centrations in adult HoFH patients with modern lipid-
lowering therapy (a statin with or without ezetimibe)
have been shown to reduce the risk of major adverse cardio-
vascular events and death.1
Pediatric patients with HoFH also urgently require lipid-
lowering pharmacotherapy to prevent atherosclerosis and
prolong life4,5; yet, data are limited on therapeutic options
in this patient population. Furthermore, in patients with
HoFH, lipid-lowering therapies are often unable to lower
LDL-C sufficiently, even when used in the highest doses
and in combination.6 In addition to lipid-lowering drugs,
LDL apheresis is the standard of care for pediatric patients
with HoFH.7 However, this therapy has limited availability,
is expensive, and is an invasive and time-consuming proce-
dure for young children. Additional therapies for pediatric
patients with HoFH are therefore needed.
Mipomersen is an antisense oligonucleotide that inhibits
the synthesis of apolipoprotein B (apo B)–100 without
reliance on LDL-receptor function (Fig. 1).8 In the United
States, mipomersen (marketed as Kynamro) is indicated
for use as an adjunct to lipid-lowering medications and
modified diet to reduce LDL-C, apo B–100, totalFigure 1 Mipomersen mechanism of action. apo B–100, apoli-
poprotein B–100; LDL-C, low-density lipoprotein cholesterol;
mRNA, messenger ribonucleic acid; RNase H, ribonuclease H;
VLDL, very low density lipoprotein. Reprinted from the Journal
of the American College of Cardiology, Vol. 62/No.23, Thomas
GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M, Mipo-
mersen, an apolipoprotein B synthesis inhibitor, reduces athero-
genic lipoproteins in patients with severe hypercholesterolemia
at high cardiovascular risk: A Randomized, Double-Blind, Pla-
cebo-Controlled Trial, pp 2178–2184, Copyright 2013, with
permission from the American College of Cardiology Foundation.cholesterol, and non–high-density lipoprotein cholesterol
concentrations in patients with HoFH.9 However, safety
and efficacy of mipomersen have not been established in
pediatric patients.9
We present here a posthoc subanalysis of 7 pediatric
patients (aged 12 to 18 years) with HoFH who participated
in a 26-week phase 3, randomized double-blind, placebo-
controlled trial (RCT, NCT00607373) of mipomersen and
its 52-week or 104-week open-label extension study (OLE,
NCT00694109). This analysis includes the efficacy and
safety of mipomersen in these 7 pediatric patients who were
all taking a maximally tolerated statin, a cholesterol-
absorption inhibitor, a bile acid sequestrant, and/or nico-
tinic acid.10 The design, methods, and results of the RCT
and the OLE have been previously published.10,11Methods
Study participants
For entry into the RCT, patients aged had to be
$12 years with either a genetic confirmation of HoFH
or a clinical diagnosis based on an untreated LDL-C
concentration of .500 mg/dL (or .13 mmol/L), together
with either xanthoma before 10 years of age or evidence of
heterozygous familial hypercholesterolemia in both par-
ents.10 Patients were required to be stable on a low-fat diet
and on a preexisting, maximally tolerated lipid-lowering
drug (a statin, a cholesterol-absorption inhibitor, a bile
acid sequestrant, nicotinic acid, or a combination
thereof).10 Also, patients had a fasting LDL-C concentra-
tion of $130 mg/dL, triglyceride concentration of
,350 mg/dL, and body weight of $40 kg.10 Patients
receiving LDL apheresis within 8 weeks of the screening
visit were excluded.10 Additional exclusion criteria
included significant cardiovascular events within 12 weeks
of screening, unstable or inadequately treated stable
angina, congestive heart failure, uncontrolled hypothyroid-
ism, or any other disorder that might predispose to second-
ary hyperlipidemia, serum creatine phosphokinase levels
$3 times the upper limit of normal, or a history of signif-
icant renal or hepatic disease.10 For entry into the OLE,
patients had to have satisfactorily completed dosing and
week 28 assessments in the RCT and had to have an
acceptable safety profile.11 Both the RCT and OLE
required that the parents and/or legal guardians give
informed consent, and, if appropriate for the patient’s
age that the patient give consent and/or assent for study
participation.10,11
Study design
Descriptions of the design of the initial clinical trial and
the main study population have been previously published.10
After a screening phase of #4 weeks, patients were
randomly assigned in a 2:1 ratio to 26 weeks of
Table 1 Baseline characteristics of pediatric patients
Patient
number
Age
(y) Ethnicity Gender BMI
LDLR genetic
mutations Medical history Medications
1 14 Caucasian Female 24.0 D206 E/V408 M Probable aortic valve stenosis, cutaneous xanthomas, tendon xanthomas on Achilles tendons,
multiple verrucae, arcus cornealis
Oral atorvastatin,
oral ezetimibe
2 14 Caucasian Female 25.7 D206 E/D206 E Probable aortic valve stenosis, cutaneous xanthomas, tendon xanthomas on Achilles tendons Oral atorvastatin,
oral ezetimibe
3 16 Caucasian Male 16.6 D69 A/NA Coronary artery disease, bilateral carotid bruit, thalassemia minor, scoliosis, asthma, spinal
surgery with rod placement, cervical spine shaving surgery
Oral atorvastatin,
oral ezetimibe
4 13 Caucasian Female 30.0 D206 E/D206 E Aortic valve incompetence, aortic valve stenosis, chest pain, cutaneous xanthomas, tendon
xanthomas, tonsillectomy, aortic root repair operation
Oral atorvastatin,
oral ezetimibe,
omega 3 fish oil
5 14 Caucasian Female 35.0 D206 E/D206 E Aortic valve stenosis, cutaneous xanthomas, tendon xanthomas on Achilles tendons, acne,
arcus cornealis, renal calculus, anemia, menorrhagia
Oral atorvastatin
6 12 Caucasian Male 19.7 D206 E/D154 N Aortic valve stenosis, angina pectoris, cutaneous xanthomas, tuberous xanthomas, tendon
xanthomas on Achilles tendons, arcus cornealis, xanthelasma, syncopal episodes, excision
of tuberous xanthoma
Oral atorvastatin,
oral ezetimibe
7 12 Black Male 23.1 W66 G/D321 N Low hemoglobin levels Oral atorvastatin,
oral ezetimibe,
omega 3 fish oil
supplement
BMI, body mass index; LDLR, low-density lipoprotein receptor; NA, not available.
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Raal et al Pediatric experience with mipomersen 863treatment with mipomersen 200 mg per week (160 mg if
body weight was ,50 kg) or a matching volume of
placebo administered subcutaneously (SC).10 After
completion of the RCT, all the pediatric patients volun-
tarily enrolled in the OLE, which offered either 52
(1 year) or 104 weeks (2 years) of mipomersen treatment,
followed by a 24-week posttreatment follow-up period.11
All patients were on maximally tolerated lipid-lowering
therapy during the active treatment phase and were not
permitted to change their background lipid-lowering
drug during the RCT.10,11
Efficacy assessments
The primary endpoint was the percentage change in
LDL-C concentration from baseline to the end of the
RCT.10,11 Prespecified secondary efficacy measures were
percentage change from baseline in apo B, total cholesterol,
and non–high-density lipoprotein-C (HDL-C) concentra-
tions.10,11 Prespecified tertiary efficacy endpoints were
changes in concentrations of lipoprotein(a) [Lp(a)], triglyc-
erides, very low density lipoprotein cholesterol, HDL-C,
apolipoprotein A1, and change in the ratio of LDL-C to
HDL-C.10,11 Blood and urine samples taken after at least
10 hours of fasting were obtained at every visit.10,11 All
laboratory assessments specified in the protocol were per-
formed at a central laboratory in either Cincinnati, OH,
USA, or Leuven, Belgium.10,11
Safety assessments
Safety assessments included all adverse events (AEs)
and changes in liver transaminases and liver fat. Laboratory
abnormalities had to be confirmed by repeat blood draw
and retest (ideally in the same central laboratory) ideally
drawn within 3 days of and no more than 5 days of the
initial blood draw. Unless contraindicated, magnetic reso-
nance imaging was used to assess liver fat fraction at
baseline10 and at approximately 6-month intervals during
the OLE. Another measurement of hepatic fat was recom-
mended in patients with confirmed increases in alanine
aminotransferase (ALT) levels of $3 times the upper limit
of normal.10 All magnetic resonance imaging readings of
hepatic fat content were undertaken at a core facility by
one assessor who was masked to the treatment group.10
Safety and tolerability of mipomersen were also assessed
by withdrawals, including the protocol-defined rules for
discontinuation of a study drug (stopping rules), which
were increases in ALT levels ($5 times the upper limit
of normal confirmed on retest within 5 days, or 3 times
the upper limit of normal in the presence of a bilirubin
higher than the upper limit of normal confirmed on retest),
renal dysfunction, or thrombocytopenia.10 Additional pre-
defined outcomes of interest were the assessment of
influenza-like symptoms, injection-site reactions, and
high-sensitivity C-reactive protein.10Statistical analyses
Patients were evaluated at the primary efficacy time
point and at the end of the OLE period for percentage
change from baseline in LDL-C and apo B concentrations.
The primary efficacy time point for the RCT was specified
as 14 days after the last dose of the treatment period. The
primary efficacy time point was at week 28 of the 26-week
RCT treatment period.10 AEs were summarized using
descriptive statistics.Results
Patient demographics and characteristics
This subanalysis of the 51 patients evaluated in the RCT
included 7 patients (14%) who were aged 12 to 18 years.10
All 7 pediatric patients had genetic confirmation of HoFH.
Baseline characteristics of the 7 pediatric patients are pro-
vided in Table 1. Remarkably, 5 of the 7 patients already
had or were suspected to have aortic valve stenosis, as-
sessed clinically as a significant murmur across the aortic
valve or on echocardiography. Of the 7 pediatric patients,
3 (patient numbers 1 to 3, henceforth referred to as patient
1, 2, 3) were randomized to SC mipomersen 200 mg once
weekly for 26 weeks, and 4 patients (patients 4 to 7) were
randomized to placebo (Fig. 2).10 All 7 patients tolerated
the study treatment, satisfactorily completed the RCT
requirements, and entered the OLE study.10 One patient,
patient 6, weighed ,50 kg and thus received SC
mipomersen 160 mg once weekly in the OLE study.
Efficacy
Baseline LDL-C concentrations in the 3 patients
receiving mipomersen ranged from 538.0 mg/dL to
633.5 mg/dL and were 241 mg/dL to 386 mg/dL at the
end of the trial (30.8% to 62.0% reduction). In contrast, 3 of
the 4 pediatric patients who received placebo had relatively
stable LDL-C concentrations (7.9% decrease to a 3.0%
increase), and the remaining patient had a 43.1% increase
(Table 2, Fig. 3).
One patient (patient 4) displayed fluctuating responses to
treatment, which was considered likely due to dose in-
terruptions during weeks 24, 27–29, and 37 and which was
reflected by plasma drug concentrations.
Similar reductions to those seen in LDL-C concentra-
tions were noted in total apo B concentrations. Over
26 weeks, reductions from baseline ranged from 32.8% to
62.2% for recipients of mipomersen compared with essen-
tially no change in 3 recipients of placebo and a 29.2%
increase in the fourth (patient 5; Table 3, Fig. 4). Baseline
apo B concentrations were higher in patients receiving
mipomersen (311–415 mg/dL) than in patients receiving
placebo (228–300.5 mg/dL).
Figure 2 Pediatric patient flow in randomized controlled trial and open-label extension. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; OLE, open-label extension study; RCT, randomized controlled trial.
864 Journal of Clinical Lipidology, Vol 10, No 4, August 2016Most pediatric patients experienced reductions in Lp(a)
concentrations with mipomersen (Fig. 5). All 3 patients
initially randomized to receive mipomersen showed reduc-
tions in Lp(a) during the RCT. Among the patients initially
given placebo, 2 of the 4 showed reductions in Lp(a) with
mipomersen during the OLE, and Lp(a) concentrations
were unchanged or increased for the remaining 2 patients.
During the OLE, 2 patients who had received mipo-
mersen during the RCT experienced increases in LDL-C
and apo B concentrations that returned to levels near
baseline in the RCT. One patient continuing mipomersen
from the RCT stopped the trial shortly after the OLE began
(week 39) due to injection-site reactions and systemicTable 2 Effects of mipomersen on LDL-C concentration
Patient
number
Treatment,
RCT/OLE
Baseline
LDL-C, mg/dL
RCT primary endpoint
at week 28 LDL-C,
mg/dL
A
c
L
1 MIPO/MIPO 558.0 386 2
2 MIPO/MIPO 538.0 348 2
3 MIPO/MIPO 633.5 241 2
4 PBO/MIPO 466.0 429
5 PBO/MIPO 399.0 571
6 PBO/MIPO 475.5 488
7 PBO/MPO 332.0 342
LDL-C, low-density lipoprotein cholesterol; MIPO, mipomersen; OLE, open-l
*This patient exhibited greater decreases in LDL-C concentrations (range:
†This patient weighed ,50 kg and was treated with subcutaneous mipomeinflammatory response lasting 2 to 3 days. At the time of
discontinuation, LDL-C and apo B concentrations were
comparable to those at the end of the RCT. Of the 4
pediatric patients previously randomized to placebo during
the RCT, 3 responded well to mipomersen, with reductions
in LDL-C concentrations from OLE baseline ranging from
26.5% to 42.1% for patients 5 to 7. Patient 4 had an 11.2%
increase in LDL-C concentration. The reason for this
apparent lack of response is unclear but is likely explained
by dose interruptions. Mipomersen was associated with a
similar pattern for plasma levels of apo B in these patients;
patient 5, 6, and 7 had reductions of 24.3% to 44.2%, and
patient 4 had a 14.9% increase.bsolute
hange in
DL-C
% Change in
LDL-C at week 28
OLE week of
last dose
OLE % change
in LDL-C
172.0 230.8 39 234.9
190.0 235.3 83 3.9
392.5 262.0 130 28.0*
237.0 27.9 52 11.2
172.0 43.1 52 242.1
12.5 2.6 26 234.2†
10.0 3.0 17 226.5
abel extension study; PBO, placebo; RCT, randomized control trial.
275.2% to 243.6%) until the final measurement.
rsen 160 mg once weekly as per protocol.
Figure 3 Low-density lipoprotein cholesterol concentration at measured time points in the randomized controlled trial and the open-label
extension study. LDL-C, low-density lipoprotein cholesterol; OLE, open-label extension study; RCT, randomized controlled trial.
Raal et al Pediatric experience with mipomersen 865Safety
Of the 3 recipients of mipomersen in the 26-week RCT,
2 had$1 AE (Table 4). AEs consisted of erythema, pain, or
discoloration at the injection site and flu-like symptoms.
Injection-site pain was reported in 2 of the 4 patients who
received placebo. In both the RCT and the OLE, the most
common AE was injection-site reaction. Serum ALT con-
centrations increased to $3 times the upper limit of normal
(ie,$90 U/L) during mipomersen therapy in 2 pediatric pa-
tients. In patient 4, the ALT increased from 21 U/L at base-
line to 130 U/L at week 26. In patient 6, the ALT increased
from 27 U/L at baseline to 187 U/L at week 26 but
decreased to 37 U/L at 24 weeks after the last mipomersen
dose. Percent liver fat fraction did not increase significantlyTable 3 Effects of mipomersen on apo B concentration
Patient
number
Treatment,
RCT/OLE
Baseline apo
B, mg/dL
RCT primary endpoint
at week 28: apo B,
mg/dL
Abso
in ap
1 MIPO/MIPO 311.0 209 210
2 MIPO/MIPO 334.0 189 214
3 MIPO/MIPO 415.0 157 225
4 PBO/MIPO 300.5 288 21
5 PBO/MIPO 244.5 316 7
6 PBO/MIPO 269.5 269 2
7 PBO/MPO 228.0 228
apo B, apolipoprotein B; MIPO, mipomersen; OLE, open-label extension stuin association with mipomersen treatment (Table 5). Four
patients discontinued because of injection-site reactions,
flu-like symptoms, or elevated liver enzymes.
Discussion
This was a subanalysis of pediatric patients (aged 12–
18 years) enrolled in an RCT with an OLE in patients with
HoFH treated with mipomersen. Overall, mipomersen
lowered LDL-C, apo B, and Lp(a) concentrations in
pediatric patients who were already on a low-fat diet and
the maximally tolerated dose of statin and/or ezetimibe.
Additionally, similar reductions in all measured atherogenic
lipoproteins were seen in the pediatric patients compared
with the adult cohort with HoFH. In the RCT, the overalllute change
o B
% Change in apo
B at week 28
OLE week of
last dose
OLE % Change
in apo B
2.0 232.8 39 229.8
5.0 243.4 83 21.5
8.0 262.2 130 222.6
2.5 24.2 52 14.9
1.5 29.2 52 244.2
0.5 20.19 26 234.1
0.0 0.0 17 224.3
dy; PBO, placebo; RCT, randomized controlled trial.
Figure 4 Apo B concentration at measured time points in the randomized controlled trial and the open-label extension study. apo B,
apolipoprotein B; OLE, open-label extension study; RCT, randomized controlled trial.
866 Journal of Clinical Lipidology, Vol 10, No 4, August 2016patient population receiving mipomersen experienced mean
reductions from baseline of approximately 25% and 27% in
LDL-C and apo B concentrations, respectively.10 In the
RCT, the 3 pediatric patients receiving mipomersen experi-
enced mean reductions from baseline of approximatelyFigure 5 Lipoprotein(a) concentration at measured time points in th
Lp(a), lipoprotein(a); OLE, open-label extension study; RCT, randomiz43% and 46% for LDL-C and apo B, respectively. At semi-
annual intervals over the course of the OLE, the overall
population had decreases in mean LDL-C concentrations
of 27% to 28% and in mean apo B concentrations of
28% to 31%.11 In the present subanalysis, pediatric patientse randomized controlled trial and the open-label extension study.
ed controlled trial.
Table 4 Adverse effects in pediatric patients receiving
mipomersen compared with placebo
Adverse event (AE)
Incidence in RCT, n
Mipomersen
(n 5 3)
Placebo
(n 5 4)
Any AE 2 3
Injection-site erythema 1 0
Injection-site pain 1 2
Injection-site discoloration 2 0
Flu-like symptoms 1 0
RCT, randomized controlled trial.
Raal et al Pediatric experience with mipomersen 867had substantial variations in response. At final assessment
of the OLE, 2 patients (1 receiving placebo in the RCT
and the other receiving mipomersen) had increases in
LDL-C concentrations compared with the RCT final mea-
surement. The other 4 patients had reductions in LDL-C
concentrations ranging from 28.0% to 242.1%. The re-
sults for Lp(a) are consistent with recent data for adults
in 4 randomized trials of mipomersen vs placebo showing
a reduction of approximately 26% in Lp(a) with mipo-
mersen and no change with placebo.12 In an analysis of
LDL-C and Lp(a) over the time course of the OLE, it is
clear that these patients often experienced fluctuations in
lipid measurements, suggesting that the final assessment
time point may not adequately depict the efficacy of mipo-
mersen in the pediatric population. After 40 weeks of ther-
apy with mipomersen during the OLE study, plasma levels
of apo B–containing lipoproteins tended to fluctuate or in-
crease in some patients. One plausible explanation for this
is poor adherence to the study medication, as reflected by
plasma drug concentrations. In this study, mipomersen
was dosed weekly via SC injection. Study visits occurredTable 5 Alanine aminotransferase (ALT) concentration and
liver fat fraction in pediatric patients treated with
mipomersen*
Patient
number Visit ALT, U/L
Liver fat
fraction, %
3 Baseline 13 —
Week 138 12 0.01
Week 24 postdose 17 0.35
4 Baseline 21 22.6
Week 26 130 23.35
5 Baseline 13 21.33
Week 52 34 1.71
Week 24 postdose 20 21.79
6 Baseline 27 23.3
Week 26 187 21.57
Week 24 postdose 37 —
*Long-term liver fat fraction data only available for the 4 patients
listed.every 4 to 5 weeks during most of the RCT and every 4
to 7 weeks during most of the OLE.10,11 The responsibility
was left to the patients’ caregivers and the children them-
selves to comply with the weekly injections between study
visits. These may not have occurred consistently in this
study.
Underdiagnosis and undertreatment of pediatric familial
hypercholesterolemia is an important clinical problem that
was recently the subject of a new position statement by the
European Atherosclerosis Society Consensus Panel.13 In
this study, 5 of 7 pediatric patients had aortic valve disease
that likely was due to their markedly elevated LDL-C
levels. This finding highlights the severity of HoFH, the
presence of important complications in these patients, and
the need for effective treatment. In the pediatric population
in particular, adherence to therapy is crucial. Studies
regarding patient adherence indicate that patients who do
not fully accept the severity of their condition or fully
recognize the benefits of a medication may exhibit poor
compliance, emphasizing the importance of communica-
tion between the provider and the patient.14 Given that car-
diovascular events tend to be associated with aging and to
be acute in nature, the pediatric population may not feel a
sense of urgency for maintaining compliance with a preven-
tive medication. In fact, HoFH is generally a silent disease
until a cardiovascular event occurs. Therefore, poor adher-
ence to therapy is also a common concern within the overall
familial hypercholesterolemia population. Finally, SC in-
jections, including those associated with injection-site reac-
tions in most patients, may be troublesome in a pediatric
population due to fear of needle-sticks. However, pediatric
patients with diabetes have overcome this issue, so it is not
insurmountable. All pediatric patients in our study had at
least 1 study protocol deviation related to drug administra-
tion and/or study procedures, in some cases reflecting diffi-
culty in traveling to the study center or conflicts with school
schedules. Nearly half of the patients in our study
completed their assigned treatment phase, either 1 year
(n 5 2) or 2 years (n 5 1), thus demonstrating that adher-
ence in this population is achievable. The remaining 4 pa-
tients experienced AEs sufficient to cause discontinuation.
These were related to injection-site reactions, flu-like
symptoms, or elevated liver enzymes, which represent po-
tential concerns that may affect compliance. Clinicians
who are treating the pediatric population with HoFH should
be aware of potential issues with adherence to therapy.Conclusions
In this subanalysis of the pediatric patients from a large
HoFH RCT with an OLE, mipomersen lowered LDL-C,
apo B, and Lp(a) concentrations in patients who were
already on the maximally tolerated dose of statin and/or
ezetimibe and a low-fat diet. The safety profile for
mipomersen in this study was consistent with those seen
in other phase 3 clinical trials. Mipomersen represents a
868 Journal of Clinical Lipidology, Vol 10, No 4, August 2016potential new additional treatment option for pediatric
patients with HoFH.Acknowledgments
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Appendix
Case studies
Patient 1
Patient 1 was a 14-year-old Caucasian female of neither
Hispanic nor Latino origin, with a baseline body mass
index (BMI) of 24.2 kg/m2. Genetic testing performed in
1996 revealed that patient 1 had 2 mutated alleles at the
LDLR gene locus Afrik FH1/2 (D206 E/V408 M). In addi-
tion to a diagnosis of HoFH, the patient’s medical history
consisted of probable aortic valve stenosis, cutaneous xan-
thomas (interdigital and both elbows), tendon xanthomas
on Achilles tendons (bilateral), multiple verrucae on both
thumbs, and arcus cornealis. Prior and concomitant lipid-
lowering medications included atorvastatin 80 mg and eze-
timibe 10 mg orally once daily. Patient 1 received therapeu-
tic counseling during treatment.
Patient 2
Patient 2 was a 14-year-old Caucasian female of neither
Hispanic nor Latino origin, with a baseline BMI of
25.3 kg/m2. Genetic screening performed in 1998 showed
2 mutated alleles at the LDLR gene locus Afrik familial hy-
percholesterolemia 1/1 (D206 E/D206 E). In addition to a
diagnosis of HoFH, the patient had a medical history of
probable aortic valve stenosis, cutaneous xanthomas, and
tendon xanthomas on Achilles tendons (bilateral). Prior
and concomitant lipid-lowering medications used by pa-
tient 2 included atorvastatin 80 mg once daily and oral eze-
timibe 10 mg once daily. Patient 2 received therapeutic
counseling during treatment.
Patient 3
Patient 3 was a 16-year old Caucasian male of neither
Hispanic nor Latino origin, with a baseline BMI of
16.6 kg/m2. Genetic testing performed in 2001 showed
LDLR mutation type I (D69 A, exon 3, allele 1) and
LDLR mutation type II (N/A, allele 2). In addition to a
diagnosis of HoFH, the patient had a medical history of
coronary artery disease, bilateral carotid bruit, thalassemia
minor, scoliosis, asthma, spinal surgery with rod place-
ment, and cervical spine shaving surgery. Prior and
concomitant lipid-lowering medications used by patient 3
included oral atorvastatin 80 mg once daily and oral ezeti-
mibe 10 mg once daily. Patient 3 received therapeutic
counseling during treatment.
Patient 4
Patient 4 was an overweight (baseline BMI 5 28.6
kg/m2), 13-year old Caucasian female of neither Hispanic
nor Latino origin. Her genetic screening was performed
in 2001 and revealed 2 mutated alleles at the LDLR gene
locus Afrik FH 1/1 (D206 E/D206 E). In addition to a diag-
nosis of HoFH, the patient’s medical history also included
aortic valve incompetence, definite aortic valve stenosis,
chest pain (possible angina pectoris), cutaneous xanthomas,
tendon xanthomas on Achilles tendons (bilateral), tonsil-
lectomy, and aortic root repair operation. The patient’s
prior and concomitant lipid-lowering medications included
oral atorvastatin 80 mg once daily, oral ezetimibe 10 mg
once daily, and omega 3 fish oil (EPA 70 mg and DHA
46 mg once daily). Patient 4 received therapeutic coun-
seling during treatment.
Patient 5
Patient 5 was an obese (baseline BMI 5 34.4 kg/m2),
14-year old Caucasian female of neither Hispanic nor
Latino origin. The patient’s genetic testing was performed
in 2004 and confirmed 2 mutated alleles at the LDLR gene
locus Afrik FH 1/1 (D206 E/D206 E). In addition to a diag-
nosis of HoFH, her medical history included aortic valve
stenosis, cutaneous xanthomas, tendon xanthomas on
Achilles tendons (bilateral), acne, arcus cornealis, renal
calculus, anemia, and menorrhagia. The patient’s prior
and concomitant lipid-lowering medications included oral
atorvastatin 80 mg once daily. She received therapeutic
counseling during treatment.
Patient 6
Patient 6 was a 12-year-old Caucasian male of neither
Hispanic nor Latino origin, with a baseline BMI of
19.6 kg/m2. The patient’s genetic testing performed in
2001 confirmed 2 mutated alleles at the LDL receptor
gene locus Afrik FH1/3 (D206 E/D154 N). He had a
medical history of HoFH, aortic valve stenosis, infre-
quent effort-induced chest pain, angina pectoris, cuta-
neous xanthomas, tuberous xanthomas, tendon
xanthomas on Achilles tendons (bilateral) and on
extensor tendons of both hands, arcus cornealis, xanthe-
lasma, syncopal episodes in 2002 and 2007, and excision
of tuberous xanthoma on left knee. The patient’s prior
and concomitant lipid-lowering medications included
oral atorvastatin 80 mg once daily and oral ezetimibe
10 mg once daily, and he received therapeutic counseling
during treatment.
Patient 7
Patient 7 was a 12-year old African-American male of
neither Hispanic nor Latino origin, with a baseline BMI of
24.0 kg/m2. The patient’s genetic testing was performed in
2000 and revealed W66 G in exon 3, F261S in exon 6, and
D321 N in exon 7 of the LDLR gene. In addition to a diag-
nosis of HoFH, the patient also had a medical history of
low hemoglobin levels. The patient’s prior and concomitant
lipid-lowering medications included oral atorvastatin
80 mg once daily, oral ezetimibe 10 mg once daily, and
omega 3 fish oil supplement (1000 mg once daily) for
HoFH. The patient and his parent received therapeutic
counseling by a dietitian.
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